Ads
related to: pulmonary adenocarcinoma with metastasis- Treatment Modifications
View Treatment Modifications
To Manage Adverse Reactions.
- See Dosing Schedules
Find Dosing Information For This
1L NSCLC Dual I-O Option Today.
- View All Indications
Explore All Indications And See
The Range Of Treatment Options.
- Prep & Admin
Preparation & Administration For
Lung Cancer Immunotherapy.
- Treatment Modifications
Search results
Results From The WOW.Com Content Network
Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer, it is characterized by distinct cellular and molecular features. [1] It is classified as one of several non-small cell lung cancers (NSCLC), to distinguish it from small cell lung cancer which has a different behavior and prognosis.
Lung cancer, also known as lung carcinoma, is a malignant tumor that begins in the lung. Lung cancer is caused by genetic damage to the DNA of cells in the airways, often caused by cigarette smoking or inhaling damaging chemicals.
Similar to most other forms of lung carcinoma, LCLC-RP may spread ("metastasize") in three major ways — by local extension and infiltration into surrounding tissues, by lymphatic spread to regional lymph nodes, and through the bloodstream (hematogeneous metastasis) to distant organs and tissues such as the liver, brain, and skeleton.
Nearly 40% of lung cancers are adenocarcinomas, which usually originates in peripheral lung tissue. [10] Most cases of adenocarcinoma are associated with smoking; however, among people who have smoked fewer than 100 cigarettes in their lifetimes ("never-smokers"), [ 11 ] adenocarcinoma is the most common form of lung cancer. [ 12 ]
Lung cancer staging is the assessment of the extent to which a lung cancer has spread from its original source. As with most cancers, staging is an important determinant of treatment and prognosis. In general, more advanced stages of cancer are less amenable to treatment and have a worse prognosis.
In 2016, the FDA approved atezolizumab for the treatment of people with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy and pembrolizumab for the treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors express programmed death-ligand 1 as ...